Details for Patent: 9,126,941

« Back to Dashboard

Which drugs does patent 9,126,941 protect, and when does it expire?

Patent 9,126,941 protects XTANDI and is included in two NDAs.

This patent has one hundred and thirty-seven patent family members in twenty-eight countries.

Summary for Patent: 9,126,941

Title:	Treatment of hyperproliferative disorders with diarylhydantoin compounds
Abstract:	The present invention relates to diarylhydantoin compounds, including diarylthiohydantoins, and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer.
Inventor(s):	Charles L. Sawyers, Michael E. Jung, Charlie D. Chen, Samedy Ouk, Chris Tran, John Wongvipat
Assignee:	University of California San Diego UCSD
Application Number:	US13/448,964
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,126,941
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Dosage form;

Drugs Protected by US Patent 9,126,941

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Astellas	XTANDI	enzalutamide	CAPSULE;ORAL	203415-001	Aug 31, 2012		RX	Yes	Yes	9,126,941					TREATMENT OF PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (CRPC)
Astellas	XTANDI	enzalutamide	CAPSULE;ORAL	203415-001	Aug 31, 2012		RX	Yes	Yes	9,126,941					THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC)
Astellas	XTANDI	enzalutamide	CAPSULE;ORAL	203415-001	Aug 31, 2012		RX	Yes	Yes	9,126,941					THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER

International Family Members for US Patent 9,126,941

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1893196		C300632	Netherlands
European Patent Office	1893196		CA 2013 00065	Denmark
European Patent Office	1893196		PA2013029	Lithuania